Today's Rundown Ultragenyx snags option on antisense startup GeneTx In conversation with Samumed CEO Osman Kibar: Drugging Wnt, restoring youth and unconventional capital Y-mAbs ramps up head count in post-IPO hiring spree MacroGenics, Incyte’s PD-1 med to face off with Merck’s Keytruda in a first for cancer R&D AstraZeneca drug heads to phase 2 in pancreatic cancer after small trial extends survival Featured Story | Thursday, August 15, 2019 Ultragenyx has picked up an option to acquire GeneTx and its preclinical antisense oligonucleotide. The drug, GTX-102, is designed to treat the rare neurogenetic disorder Angelman syndrome. |
|
| Top Stories Thursday, August 15, 2019 Samumed CEO Osman Kibar discusses regenerative medicine, drugging the Wnt pathway and his company's unorthodox journey. Thursday, August 15, 2019 Y-mAbs Therapeutics has rapidly expanded its headcount by 65%. The post-IPO hiring spree comes as Y-mAbs heads toward FDA filings of two cancer drugs later this year. Thursday, August 15, 2019 It has the makings of a David and Goliath story: MacroGenics will kick off a trial later this year that will pit its Incyte-partnered anti-PD-1 drug against Merck’s Keytruda—the first drug of its class to win approval—in patients with head and neck cancer. Thursday, August 15, 2019 University of Michigan researchers are reporting promising results from an early trial of AstraZeneca’s AZD1775, a drug that blocks an enzyme cancer cells need to repair their own DNA. Resources Sponsored by: Wesco Pharmaceutical Solutions and WBR Insights The regulations and managing processes for hazardous, controlled and rare chemicals and biologics necessary for drug discovery are a huge distraction for R&D labs. Learn from the perspectives of industry executives the pain points and improvements they want in their processes for chemicals and biologics in pharmaceuticals R&D. Sponsored by: Kinaxis Download this life sciences industry spotlight to discover how concurrent planning can help you overcome complex supply chain challenges to drive down costs and improve efficiency. Sponsored by: Patheon, by Thermo Fisher Scientific Patheon, part of Thermo Fisher Scientific, offers advanced API manufacturing technologies such as continuous processing and continuous analytics to deliver high-quality products with well-defined features to meet your timelines and volume requirements. Sponsored by: ICON Understanding the challenges for formulary decision makers and manufacturers. Sponsored by: Veeva This white paper details how leveraging new reporting capabilities, live UAT feedback sessions, and an agile design approach to study builds will save them time and money. Sponsored by: BBK Worldwide The Study Voices survey challenges the myth that physicians won’t refer patients to clinical trials, and it identifies opportunities to engage physicians as partners in the enrollment process. Sponsored by: Cambrex The highest number of NCEs approved by the FDA…the fastest growing small molecule clinical pipeline reported in 20 years…these are exciting times for our industry. Sponsored by: Reprints Desk, Inc. Cut your research time in half - with an easy-to-use app for scientists that combines full-featured reference management with integrated search and on-demand document delivery. Sponsored by: XiltriX North America Find out in this article how your pharmaceutical organization can leverage IoT technologies and informatics integration to innovate and improve overall operational efficiencies. Sponsored by: Catalent Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study. Sponsored by: Catalent Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels. Sponsored by: Catalent Download the eBook to explore a proactive approach for clinical supply management. Latin America Healthcare Compliance Certificate Program September 23-26, 2019 4th FierceBiotech Drug Development Forum October 28-29, 2019 | Boston, MA Drug Development Boot Camp® 2019 November 20-21, 2019 | Boston, MA | Register NOW and start Pre-Boot Camp Preparation! |